Keros Therapeutics (KROS) Shares Outstanding (Weighted Average) (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $37.2 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) fell 0.58% year-over-year to $37.2 million; the trailing twelve-month figure through Dec 2025 stood at $37.2 million (down 0.58% YoY), and the FY2025 full-year result was $37.2 million, down 0.58% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $37.2 million, down from $40.6 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $40.6 million in Q3 2025 and bottomed at $23.2 million in Q1 2021.
• The 5-year median for Shares Outstanding (Weighted Average) is $29.5 million (2023), against an average of $30.7 million.
• The widest annual swing landed in 2021, when Shares Outstanding (Weighted Average) soared 835.16%; it then retreated 0.58% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $23.3 million in 2021, then advanced by 8.17% to $25.2 million in 2022, then rose by 16.66% to $29.4 million in 2023, then grew by 27.14% to $37.4 million in 2024, then declined by 0.58% to $37.2 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $37.2 million (Q4 2025), $40.6 million (Q3 2025), and $40.6 million (Q2 2025), per Business Quant data.

Peer Comparison